Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
26.4.2022 15:45:00 EEST | Business Wire | Press release
Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion’s proprietary PIONEER® AI technology, with KEYTRUDA® (pembrolizumab) for the treatment of patients with metastatic melanoma.
“We believe we have found the key to efficiently activating the immune system to combat cancer. With our core AI tool called PIONEER, we accurately predict the patient’s most potent neoepitopes, which are the significant mutations of cancer. Then we train the immune system to target those exact mutations, not everything else. That means a higher precision in the therapy than the standard of care treatments out there,” said Lars Wegner, CEO of Evaxion. “We are happy to work with Personalis on this crucial next step when we embark on the Phase 2b study, potentially bringing us closer to fulfilling our aspiration of saving the lives of patients with our AI-powered immunotherapy.”
“Over the past decade, a number of drugs have emerged based on the discovery that the immune system plays a key role in fighting cancer. However, the development of new therapies has been challenged by difficulties in understanding the precise interaction between cancer and the immune system,” said John West, CEO and co-founder of Personalis. “ImmunoID NeXT provides a broad set of insights on tumor and immune biology. Our collaboration with Evaxion may contribute to a better understanding of how combination therapeutics can improve patient outcomes and offer the path to companion diagnostics when relevant biomarkers are identified.”
ImmunoID NeXT® provides a comprehensive, multidimensional view of both a tumor and its immune microenvironment from a single sample. The platform consolidates multiple biomarker assays into one, including advanced analysis of mechanisms of tumor escape, human leukocyte antigen typing and loss of heterozygosity, microsatellite instability, gene expression signatures, T-cell and B-cell receptor repertoires, and immunocellular quantification. ImmunoID NeXT offers a seamless platform for discovery, from translational testing to companion diagnostics.
About Evaxion
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates, which currently includes three patient-specific cancer immunotherapies.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, expected benefits of Personalis’ collaboration with Evaxion, Personalis’ business opportunities, leadership, plans or expectations, or other future events. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, the company’s registration statement on Form S-3 filed on December 30, 2020, and the company’s prospectus supplement filed on January 3, 2022, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005194/en/
Contact information
Media Contact for Evaxion:
Katrine Hertz Mortensen
khm@evaxion-biotech.com
www.evaxion-biotech.com
+45 3010 0203
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for Personalis:
Jennifer Temple
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI-Driven Upgrade Cycle Expected to Fuel 8% Telecom Growth in 2026, NIQ Forecasts10.6.2026 14:00:00 EEST | Press release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 2026 Smartphone Forecast showing that an AI-driven upgrade cycle is expected to fuel 8% growth in the global telecom sector in 2026. As manufacturers accelerate investment in on-device AI and connected device ecosystems, consumers are increasingly prioritizing intelligence functionality, seamless integration, and premium experiences when choosing their next smartphone. The forecast suggests relatively stable conditions across the broader technology and durables market, with growth increasingly concentrated in premium segments. Europe is showing early signs of a new replacement cycle after two weaker years, while China is showing signals of modest growth despite subsidy rollbacks and a challenging comparison base. Insights from Mobile World Congress 2026 suggest a broader industry shift: smartphones are evolving from standalone communication devices into intelligent platforms that connect and orchestrate consu
Opensignal Expands Subscriber Analytics Solution, Available Globally10.6.2026 14:00:00 EEST | Press release
Opensignal® today announced the global availability of Opensignal Subscriber Analytics™, extending the solution to operators across Europe, Asia Pacific, Middle East, Africa, and the Americas, subject to market-specific availability. Operators can contact Opensignal directly to confirm availability details in their specific markets of interest. Opensignal Subscriber Analytics measures competitive subscriber switching between operators at the local market level, alongside base market share by operator and region, using the same methodology Opensignal applies across its full measurement platform. Opensignal draws that measurement from hundreds of millions of subscriber devices globally. Until now, this capability has been available to operators in the United States and Canada. The global expansion makes it accessible to operators across all regions Opensignal serves. "Operators have strong visibility into their own network and commercial performance, but almost none for their competitors
Data Center World Unveils the Inaugural Data Center World Europe 202610.6.2026 14:00:00 EEST | Press release
Data Center World, the premier event for the global data center ecosystem, unveils the launch of Data Center World Europe. Today, Data Center World Europe announces the Conference Agenda for the inaugural event. Over two days, Data Center World Europetackles the industry’s most urgent challenge: transforming Europe's data centre energy landscape. The event brings together leading operators, technologists, cloud providers, hyperscalers and energy management innovatorsto exchange actionable strategies and groundbreaking insights that drive measurable results. Attendees will leave equipped to overcome energy bottlenecks and drive the development of an AI-ready, sustainable future. Data Center World Europe takes place 13-14 October 2026 at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It will be co-located with the leading global network infrastructure event NetworkX. Register to attend here. Tara Gibb, Senior Director, Data Center World Europe said, “As the demand for A
SES to conduct share buyback transaction via acquisition of FDRs to meet obligations under its employee incentive programs10.6.2026 13:56:00 EEST | Press release
SES has decided to launch a buyback transaction for shares via acquisition of fiduciary depositary receipts (FDRs) to meet obligations under SES’s Equity Based Compensation Plan (EBCP). These FDRs will be repurchased on the basis of Article 430-15(3) of the law of 10 August 1915 on commercial companies, as amended, and will not be counted towards the 10% limit as authorized during the annual general meeting of shareholders held on April 2, 2026. Under this share buyback transaction via acquisitions of FDRs, SES may acquire up to 2,967,519 FDRs (ISIN LU0088087324) at market price for an aggregate amount not exceeding EUR 31,158,949.50. The share buyback transaction via acquisition of FDRs is expected to be completed before the date of the next annual general meeting of shareholders or sooner if the maximum number of repurchased shares is reached earlier. The buyback will be conducted in accordance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and
New Research Reveals the Next Wealth Management Divide: AI Rewards Firms Built to Scale10.6.2026 13:34:00 EEST | Press release
The next competitive divide in banking, wealth and asset management will not be defined by innovation alone, but by firms’ ability to scale it profitably. That is the central finding of new research that Objectway, a global wealthtech partner for banking, wealth and asset management firms, conducted in collaboration with FT Longitude, a specialist provider of thought leadership and research services. The report, Built to Scale, is based on a survey of 300 senior professionals across banks, wealth and asset managers in the UK, continental Europe and Canada. Altough digital transformation and AI adoption are advancing rapidly across the industry, many firms are struggling to translate investment into repeatable, profitable growth. The findings point to a market entering a new phase of competition, where scalable executionis becoming more important thaninnovation capacity alone. Reflecting on this shift, Luigi Marciano, Founder and Group CEO of Objectway, commented: “For years, the indust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom